Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Liabilities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Total Liabilities for 14 consecutive years, with $146.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 5.2% year-over-year to $146.9 million, compared with a TTM value of $146.9 million through Dec 2025, up 5.2%, and an annual FY2025 reading of $146.9 million, up 5.2% over the prior year.
  • Total Liabilities was $146.9 million for Q4 2025 at Adma Biologics, up from $137.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $200.2 million in Q3 2022 and bottomed at $121.2 million in Q2 2021.
  • Average Total Liabilities over 5 years is $166.2 million, with a median of $170.6 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 50.58% in 2022, then tumbled 30.44% in 2025.
  • Year by year, Total Liabilities stood at $135.1 million in 2021, then soared by 45.46% to $196.5 million in 2022, then dropped by 1.28% to $194.0 million in 2023, then dropped by 28.0% to $139.7 million in 2024, then increased by 5.2% to $146.9 million in 2025.
  • Business Quant data shows Total Liabilities for ADMA at $146.9 million in Q4 2025, $137.5 million in Q3 2025, and $160.1 million in Q2 2025.